- ►asnjournals.org M Epstein, GH Williams, M Weinberger, A … - Clinical Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Previous studies have shown that the selective aldosterone blocker eplerenone,
in doses of up to 200 mg/d, reduces albuminuria in patients with type 2
diabetes. This study was conducted to ascertain whether lower doses of ... Cited by 81 - Related articles - BL Direct - All 3 versions
- ►ahajournals.org N Chapman, J Dobson, S Wilson, B Dahlof, PS … - Hypertension, 2007 - Am Heart Assoc Spironolactone is recommended as fourth-line therapy for essential hypertension
despite few supporting data for this indication. We evaluated the effect among
1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood ... Cited by 73 - Related articles - All 5 versions
S Bianchi, R Bigazzi, VM Campese - Kidney International, 2006 - nature.com Experimental evidence suggests that aldosterone contributes to progressive
kidney disease. Angiotensin-converting enzyme inhibitors and angiotensin type 1
receptor antagonists suppress the renin–angiotensin system but they do ... Cited by 63 - Related articles - BL Direct - All 3 versions
- ►asnjournals.org A Chrysostomou, E Pedagogos, L MacGregor, … - Clinical Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Studies have shown that dual therapy with angiotensin-converting enzyme
inhibitors (ACEI) and either angiotensin II receptor blockers or aldosterone
receptor antagonists is more effective in reducing proteinuria than either ... Cited by 62 - Related articles - BL Direct - All 3 versions
KJ Schjoedt, K Rossing, TR Juhl, F Boomsma, … - Kidney international, 2006 - nature.com Reduction of nephrotic range albuminuria is associated with markedly improved
renal and cardiovascular outcome in patients with diabetic nephropathy.
Aldosterone has been suggested to play a role in the progression of ... Cited by 62 - Related articles - BL Direct - All 4 versions
M Bochud, J Nussberger, P Bovet, MR … - Hypertension, 2006 - Am Heart Assoc The aim of this study was to analyze the associations of plasma aldosterone and
plasma renin activity with the metabolic syndrome and each of its components. We
analyzed data from a family based study in the Seychelles made up of 356 ... Cited by 52 - Related articles - All 9 versions
J Karalliedde, G Viberti - Journal of human hypertension, 2006 - nature.com The incidence of end-stage renal disease (ESRD) is rising worldwide, accompanied
by corresponding increases in the risk of morbidity and mortality. Underlying
this trend are increasing rates of hypertension and diabetes mellitus, the ... Cited by 44 - Related articles - BL Direct - All 4 versions
M Epstein - The American journal of medicine, 2006 - Elsevier In recent years, there has been a striking paradigm shift with respect to our
understanding of the widespread effects of aldosterone. Whereas the role of
angiotensin II in mediating progressive renal disease and heart failure has ... Cited by 34 - Related articles - All 9 versions
- ►endojournals.org C Guo, D Martinez-Vasquez, GP Mendez, MF … - Endocrinology, 2006 - Endocrine Soc To determine whether mineralocorticoid receptor (MR) activation plays a role in
diabetic renal injury and whether this role differs in types 1 and 2 diabetes
mellitus, we examined the effect of a MR antagonist on renal injury in ... Cited by 30 - Related articles - BL Direct - All 4 versions
